🟢 PYXS is trading 5.4% up today following Russell Microcap Growth Index inclusion, ahead of Phase 1 MICVO data and financing decisions

PYXS is trading at $2.92 (up 5.4%), extending a sharp rally that began with a 24% jump to $2.77 on June 26, 2026. - Pyxis Oncology was added to the Russell Microcap Growth Benchmark Index today, June 29, 2026. - Investors are also focused on upcoming Phase 1 monotherapy data for the company’s lead antibody-drug conjugate (ADC), MICVO (PYX-201), expected mid-year 2026. - Speculative interest is rising as the market weighs clinical milestones against the company’s shrinking cash runway and looming financing decisions, with cash runway expected into Q4 2026.